LivaNova (NASDAQ:LIVN) reported fourth-quarter 2025 revenue of $360.9 million, a 12.1% increase over the prior year, as the company enters 2026 with a significant tailwind from improved U.S. government reimbursement rates.
Myriad Genetics (NASDAQ:MYGN) shares rose as much as 4.9% Tuesday morning after the company reported fourth-quarter results that significantly outpaced Wall Street expectations for both the top and bottom lines.
Apellis Pharmaceuticals (NASDAQ:APLS) reported a milestone fiscal year 2025, delivering total net product revenues of $689 million and achieving its first year of net profitability.
Orthofix Medical (NASDAQ:OFIX) delivered a pivotal fourth quarter to close out fiscal 2025, reaching a long-sought milestone of positive annual free cash flow while reporting a 10% jump in its global spine fixation business.
Fulcrum Therapeutics (NASDAQ:FULC) reported fourth-quarter and full-year 2025 results highlighted by positive 12-week data for its lead candidate, pociredir.
Beam Therapeutics (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
Alpharetta, Georgia-based Avanos Medical (NYSE:AVNS), a medical technology company focused on pain management and chronic care solutions, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
Henry Schein (NASDAQ:HSIC) reported a 7.7% increase in fourth-quarter net sales, reaching $3.4 billion as the company benefited from a rebound in high-margin dental equipment and specialty product demand.
Fresenius Medical Care (NYSE:FMS) reported fourth-quarter financial results that exceeded Wall Street expectations, signaling a robust conclusion to its fiscal 2025.
Allurion Technologies (NYSE:ALUR) received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its Allurion Gastric Balloon System, marking a significant expansion into the U.S. obesity care market.
Bayer has filed a lawsuit against Johnson & Johnson (NYSE:JNJ) and its subsidiary Janssen Biotech, alleging the healthcare giant is using "scientifically flawed" and misleading marketing to steal market share for its prostate cancer treatment, Erleada.
Bristol Myers Squibb (NYSE:BMY) announced Monday that its Phase 2 registrational study of Reblozyl (luspatercept-aamt) achieved its primary and key secondary endpoints, potentially expanding the drug’s use to patients with alpha-thalassemia.
